APA

Bourrié B., Bribes E., Esclangon M., Garcia L., Marchand J., Thomas C., Maffrand J. P. & Casellas P. (19991210). The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. : Proceedings of the National Academy of Sciences of the United States of America.

Chicago

Bourrié B, Bribes E, Esclangon M, Garcia L, Marchand J, Thomas C, Maffrand J P and Casellas P. 19991210. The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. : Proceedings of the National Academy of Sciences of the United States of America.

Harvard

Bourrié B., Bribes E., Esclangon M., Garcia L., Marchand J., Thomas C., Maffrand J. P. and Casellas P. (19991210). The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. : Proceedings of the National Academy of Sciences of the United States of America.

MLA

Bourrié B, Bribes E, Esclangon M, Garcia L, Marchand J, Thomas C, Maffrand J P and Casellas P. The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. : Proceedings of the National Academy of Sciences of the United States of America. 19991210.